Jingye Zhou, Eccogene CEO
November 9, 2023 03:54 AM ESTUpdated 06:32 AM
Deals
R&D

As­traZeneca puts down $185M up­front for PhI oral GLP-1 as it shoots for next-gen win

Amber Tong

As­traZeneca has re­cruit­ed a new star to its bud­ding GLP-1 show, pick­ing up an ear­ly-stage oral can­di­date from Chi­na’s Ec­co­gene in a deal fea­tur­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

A service from the Financial Times